Intuitive Surgical, Inc. (NASDAQ:ISRG) is making robotic surgery easier for hospitals to finance. Operating leases accounted for 54% of second-quarter da Vinci placements, up from 49% a year earlier. Lower upfront commitments can expand adoption, but shareholders fund equipment before collecting its lifetime returns.
Intuitive Surgical, Inc. trades at 33x forward P/E and 46x trailing P/E, versus 16x forward P/E for Stryker Corporation (NYSE:SYK). Trailing P/E uses past earnings; forward P/E uses forecasts. Growing procedure volumes and instrument sales support higher expected profits, while a fuller assessment also considers the costs excluded from adjusted earnings.
Analysts expect calendar-2026 non-GAAP adjusted EPS growth of approximately 21% for Intuitive Surgical, Inc., versus 10% for Stryker Corporation. Faster expected growth may partly justify that premium, although both are expected to grow adjusted earnings about 12% in 2027. The valuation looks demanding: superior customer retention and cash returns must carry more weight as growth converges. The peer also sells orthopedic implants and other devices, making it a broader business than a direct surgical-robotics comparison.
Also read: 10 Best AI Stocks to Buy Before They Explode
Easier Adoption Still Requires Busy Systems
Intuitive Surgical, Inc., included in Insider Monkey’s 11 Best Robotics Stocks to Buy Right Now, benefits from surgeons’ training, familiar hospital workflows, and instruments that require replacement with use. These relationships can sustain repeat purchases across a system’s life.
The early evidence is encouraging. Operating lease revenue increased 22% to $262 million in the second quarter, ahead of 19% systems revenue growth. Worldwide da Vinci procedures rose 15%, while utilization increased 3%. Instruments and accessories revenue rose 18%, demonstrating how busier systems generate additional sales beyond lease payments.
For Intuitive Surgical, Inc., usage-based arrangements match hospital payments to procedures and reimbursements. Fixed-payment leases generally impose cancellation penalties; usage-based arrangements generally have no minimum payments and allow customers to leave without a financial penalty. Easier adoption therefore makes the return on customer financing more important.
Industry conditions can slow that return. U.S. procedure growth eased to 12%, versus 20% outside the United States. Management linked some domestic softness to expired enhanced health-insurance subsidies. Delayed surgery reduces both instrument demand and usage-based receipts, while equipment remains committed.
Intuitive Surgical, Inc. charges a modest leasing premium to compensate for time and utilization risk. Similar gross margins to outright sales are useful, but they do not establish similar returns on capital: the investment stays tied up longer. Customer integration creates value only when strong relationships translate into cash growth.
Cash Returns Must Cover the Equipment Commitment
Intuitive Surgical, Inc. generated $1.97 billion of first-half operating cash flow. Subtracting $216 million of cash purchases of property and equipment leaves approximately $1.76 billion, an author calculation before acquisitions, versus approximately $1.03 billion a year earlier.
Manufacturing leased equipment already consumes operating cash through inventory. The $419 million subsequently transferred from inventory into fixed assets, including operating-lease equipment, is a noncash reclassification. Subtracting it again would double-count investment. Cash generation is substantial, although $419 million of stock compensation also supported operating cash flow and remains an economic cost.
Over a system’s life, lease receipts plus instrument and service profits must recover manufacturing, maintenance and upgrade costs while earning a return on capital. Technological change can shorten useful life or reduce resale value. Operating lease assets are depreciated over one to seven years. Actual payback depends on net receipts before upgrades or obsolescence require more spending.
Intuitive Surgical, Inc. reported second-quarter GAAP EPS of $2.29 and adjusted EPS of $2.80, with stock compensation and other exclusions explaining the difference. Both measures included a $0.08-per-share tariff-refund benefit. That illustrates why adjusted earnings can still contain temporary gains. Meanwhile, $8.63 billion of cash and investments provides capacity to finance placements without immediate borrowing pressure.
The forward P/E series shows 59x at December 31, 2025, and 38x at June 30, 2026, compared with 33x in the latest available snapshot. Some compression looks justified: procedure growth was 18% in 2025, while management expects 2026 growth near the midpoint of 13.5%–15.5%. Slower expansion and continuing investment requirements support a lower valuation. The earlier multiple offers little reason to expect a return to that level.
Conclusion
Leasing makes Intuitive Surgical, Inc. more accessible and more capital intensive. The 33x forward valuation remains demanding despite strong cash generation. Sustained procedure growth near guidance, rising utilization, and cash returns after equipment upkeep would support the premium. Weaker procedure demand, idle systems, or earlier replacements would weaken it.
READ NEXT: Roper (ROP): Are Buybacks a Better Use of Cash than More Acquisitions? and Uber (UBER) Has a Growing Insurance Bill. Is Cash Flow Keeping Up?
This article is originally published at Insider Monkey.
